Overview

Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

Status:
Terminated

Trial end date:
2018-09-10

Target enrollment:

Participant gender:

Summary

The purpose of the study is to document the effect of first line dual oral combination therapy with macitentan 10mg and tadalafil 40mg on pulmonary vascular resistance (PVR) in treatment-naïve patients with newly diagnosed pulmonary arterial hypertension (PAH).

Phase:

Phase 4

Details

Lead Sponsor:

Actelion

Treatments:

Macitentan
Tadalafil